Overview Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis Status: Not yet recruiting Trial end date: 2023-11-28 Target enrollment: Participant gender: Summary This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis Phase: Phase 2 Details Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.